State of Peptide Research 2026

Why we made this report

Peptides get far more attention online than most research topics, and the attention is uneven. Some are approved medicines tested in thousands of people; others are sold as "research chemicals" on the strength of animal studies. Readers, clinicians and journalists rarely see both groups measured the same way.

This report puts every peptide we profile on one scale: how strong the human evidence is, whether FDA has approved it, whether it is banned in sport, and how much it is actually being tested. The figures are generated from the same data as our evidence grid and the downloadable files, so they can be checked line by line.

Approval and evidence are different questions

Every profile carries two separate labels. The evidence grade describes how much good human research supports the peptide's main uses. The U.S. status records whether FDA has approved it as a medicine. The table shows how the 56 peptides fall across both.

• Approval does not always mean large trials. Setmelanotide, Afamelanotide and Elamipretide are approved with a moderate grade, typically for rare conditions where trials are necessarily small.
• The unapproved peptides with the best evidence have a medical past. The only three with a moderate grade, Sermorelin, Gonadorelin and Thymosin Alpha-1, were once FDA-approved medicines or are approved in other countries. None of the unapproved peptides has a strong grade.
• Native hormones are graded on physiology. GLP-1, GIP and ghrelin have strong evidence for what they do in the body, but they are not medicines themselves, so they count as investigational.

Where the clinical trials are

Across the 51 peptides we track, ClinicalTrials.gov lists 652 active interventional trials: recruiting, about to start, or running. They are heavily concentrated: semaglutide and tirzepatide account for 57%, and metabolic peptides for 79%.

Every peptide's trials, with phase, sponsor and completion dates, are in the clinical trial tracker.

The twenty-four unapproved peptides

These are the peptides most often sold online as "research chemicals" or discussed for healing, anti-ageing, muscle or cognition. Thirteen have no registered interventional trial at all. Seven have a trial under way: BPC-157 (2), TB-500 (1), GHK-Cu (1), MOTS-c (1), Melanotan II (1), Gonadorelin (3) and Thymosin Alpha-1 (10).

One sponsor stands out. Hudson Biotech registered five of these nineteen active trials, one each for BPC-157, TB-500, GHK-Cu, MOTS-c and Melanotan II. A registered trial is a plan, not a result, and none of these has finished.

• No registered trial is not the same as never tested. ClinicalTrials.gov opened in 2000 and registration became routine later, so earlier human studies are missing. AOD-9604 is the clearest case: it has no registered trial, yet FDA's 2024 review describes a 536-person obesity trial that found no significant weight loss. A zero here can hide negative human evidence as well as none; each profile lists the human studies we found.
• Counts cover the compound itself, not related products. Trials of full-length thymosin beta-4 medicines (such as RGN-259 eye drops) are not counted for TB-500, and trials of the prodrug fosgonimeton are not counted for dihexa. Earlier editions of this report included them.

How often results are posted

Registries record plans more reliably than outcomes. Of the completed trials in our snapshot, the share with results posted on ClinicalTrials.gov itself:

Posted results are not the same as published results. Many trials report in journals instead, U.S. rules require posting only for certain trials, and recent trials may still be inside the reporting window. Read the gap as a reason to check the journal record, not as proof that results were hidden.

Banned in sport

Eighteen of the 56 peptides fall under a section of the World Anti-Doping Agency's Prohibited List, including fourteen of the twenty-four unapproved ones: BPC-157, TB-500, MOTS-c, CJC-1295, Ipamorelin, AOD-9604, KPV, Epitalon, Melanotan II, Sermorelin, GHRP-6, GHRP-2, Hexarelin and Gonadorelin. Our guide to WADA peptide rules explains the S0 and S2 sections.

Corrections and changes

This is version 1.1 of the 2026 report, built on evidence methodology 1.0.

Reader audit. A reader review of the first edition on 12 October 2026 identified three errors, all corrected in version 1.1 and listed below. We welcome this kind of checking: if you find an error in any figure, grade or source, tell us through the corrections policy and we will correct it and log the change here, with credit if you want it.

• 2026-10-12, version 1.0. First edition published.
• 2026-10-12, version 1.1. AOD-9604 corrected after a reader audit: its WADA section is S2.2.3 (growth hormone fragments), not S0, and its grade is now early human evidence to reflect the negative obesity trials described in FDA’s 2024 briefing document. MOTS-c corrected to WADA S4.4.1. Trial matching narrowed so that full-length thymosin beta-4 medicines no longer count as TB-500 trials and the prodrug fosgonimeton no longer counts as dihexa; the trial-level download and per-peptide query expressions were added.

Use the data

The full dataset, one row per peptide, is free to reuse under CC BY 4.0 with a credit to Inside Peptides and a link to this page. Field definitions are on the data page.

Download ExcelDownload CSVReport (PDF)Explore in the evidence grid